EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy—the DANGER-emesis study

Sofie S Detlefsen, Ditte S Andersen, Anja Ø Knudsen, Trine J Nøttrup, Sören Möller, Gitte-Bettina Nyvang, Trine L Jørgensen, Jørn Herrstedt, Christina H Ruhlmann

Supportive Care in Cancer · 2025

DOI: 10.1007/s00520-025-09573-9 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Sofie S Detlefsen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Dexamethasone, Antiemetics, Palonosetron, Vomiting. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinn, Odense University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Netupitant 300 mg/palonosetron 0.5 mg (NEPA) would be ideal as antiemetic prophylaxis for patients receiving weekly cisplatin, as it would reduce concurrent medication intake compared to the 3-day aprepitant regimen. However, due to the longer half-life of netupitant (~ 88 h), weekly administration could potentially lead to accumulation and toxicity. This study aims to investigate the safety and antiemetic efficacy of weekly administration of NEPA plus dexamethasone (DEX) in patients treated for cervical cancer with radiotherapy and weekly cisplatin 40 mg/m 2 .

Methods

This single-arm, open-label, phase II study evaluated patients with cervical cancer receiving NEPA and DEX before weekly cisplatin and concomitant radiotherapy for up to 5 weeks. Safety was assessed during weekly adverse event (AE) assessments. Efficacy was evaluated using Patient Diaries reporting daily nausea, vomiting, and use of rescue medication during the study period.

Results

Between October 8, 2018, and January 2, 2024, 73 patients were recruited from two Danish departments of oncology; 37 completed all five weekly cycles. The majority of AEs were of mild or moderate intensity, with fatigue being the most frequently observed (95% of patients). Seven (10%) patients encountered ≥ 1 grade 3 treatment-related AEs (TRAEs). No grade 4 TRAEs or deaths were observed. In terms of efficacy, no vomiting and no nausea days 1–35 were 86% and 18%, respectively. Mean time to first emetic episode was 9 days.

Conclusion

Weekly NEPA administration was safe, well-tolerated, and highly effective during concomitant radiotherapy and weekly cisplatin.

Trial registration

This trial is registered at ClinicalTrials.gov (NCT03668639-2018–09-10).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneAntiemeticsPalonosetronVomitingNauseaUterine Cervical NeoplasmsPyridinesHumansFemaleMiddle AgedAgedAdultCisplatinChemoradiotherapyDrug CombinationsDrug Administration SchedulePiperazinesBenzeneacetamides

Stichwörter der Autor:innen

Concomitant chemoradiotherapyNEPANauseaNetupitantPalonosetronVomiting

Substanzen

DexamethasoneAntiemeticsPalonosetronCisplatinPyridinesDrug CombinationsnetupitantPiperazinesBenzeneacetamides

Autor:innen und Institutionen

  • Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • OPEN - Open Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Oncology, Zealand University Hospital, Roskilde, Denmark.
  • University of Copenhagen, Copenhagen, Denmark.

Förderung

  • Helsinn
  • Odense University Hospital

Zitieren

APA

Detlefsen, S. S., Andersen, D. S., Knudsen, A. Ø., Nøttrup, T. J., Möller, S., Nyvang, G. B., Jørgensen, T. L., Herrstedt, J., & Ruhlmann, C. H. (2025). Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy—the DANGER-emesis study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09573-9

Vancouver

Detlefsen SS, Andersen DS, Knudsen AØ, Nøttrup TJ, Möller S, Nyvang GB, et al. Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy—the DANGER-emesis study. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09573-9

BibTeX
@article{Detlefsen2025,
  author = {Detlefsen, Sofie S and Andersen, Ditte S and Knudsen, Anja Ø and Nøttrup, Trine J and Möller, Sören and Nyvang, Gitte-Bettina and Jørgensen, Trine L and Herrstedt, Jørn and Ruhlmann, Christina H},
  title = {Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy—the DANGER-emesis study},
  journal = {Supportive Care in Cancer},
  year = {2025},
  doi = {10.1007/s00520-025-09573-9}
}
Kostenlos starten →